Chester County News and Community Website
WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved Bizengri for adults with advanced NRG1 fusion-positive cholangiocarcinoma, marking the first approved treatment for the rare bile duct cancer …
FDA Approves Bizengri for Rare Bile Duct Cancer Read More
PHILADELPHIA, PA — Dispatch Bio said it will present new preclinical data on its SEND T cell engineering platform at the ASGCT 2026 Annual Meeting, highlighting experimental results showing anti-tumor …
Dispatch Bio Reports Preclinical Cancer Therapy Data Read More
HARRISBURG, PA — A $450 million investment to build a new pharmaceutical manufacturing facility in Philadelphia is expected to create 225 jobs and expand the production of materials used in …
$450M Pharma Plant to Bring Jobs, Cancer Research to Philly Read More
WILMINGTON, DE — The European Commission has approved Zynyz (retifanlimab), developed by Incyte (Nasdaq: INCY), in combination with carboplatin and paclitaxel for the first-line treatment of adults with metastatic or …
Incyte Drug Zynyz Approved in Europe for Anal Canal Cancer Treatment Read More
What This Means for You More than 500 new jobs are expected in Montgomery County over the next 12 years. The state will provide up to $41.5 million in financial …
Johnson & Johnson to Invest $1 Billion in Montgomery County Cancer Drug Facility Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network, on World Cancer Day, observed February 4, highlighted its free patient guidelines aimed at helping people navigate a cancer diagnosis, according …
NCCN Highlights Free Patient Cancer Guidelines on World Cancer Day Read More
WILMINGTON, DE — AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review by the U.S. Food and Drug Administration for …
DATROWAY Gains Priority Review for Aggressive Breast Cancer Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported its first unconfirmed partial response in a Phase 1 study of its experimental cancer drug APR-1051, an early signal the company …
Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial Read More
NEWARK, DE — New preclinical research from CorriXR Therapeutics suggests a novel gene-editing strategy could reopen the door to standard chemotherapy for patients whose cancers have become resistant to treatment, …
CRISPR Breakthrough Reverses Chemo Resistance in Aggressive Cancers Read More WILMINGTON, DE — AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) said their jointly developed breast cancer therapy ENHERTU has received Breakthrough Therapy Designation from the U.S. Food and Drug …
ENHERTU Scores Tenth FDA Fast-Track as Breast Cancer Data Shifts Playbook Read More